Consider This Before Taking a Position in Immunovant (IMVT)

By Chris Stiles • Tuesday, January 30 15:33 • Permanent Link

One of the losers of today's trading session was Immunovant. Shares of the Biotechnology company plunged -3.7%, and some investors may be wondering if its price of $37.85 would make a good entry point. Here's what you should know if you are considering this investment:

Immunovant has moved 121.3% over the last year, and the S&P 500 logged a change of 20.9%
IMVT has an average analyst rating of buy and is -24.65% away from its mean target price of $50.23 per share
Its trailing earnings per share (EPS) is $-1.96
Immunovant has a trailing 12 month Price to Earnings (P/E) ratio of -19.3 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $-1.93 and its forward P/E ratio is -19.6
The company has a Price to Book (P/B) ratio of 19.75 in contrast to the S&P 500's average ratio of 2.95
Immunovant is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
The company has a free cash flow of $-107997000, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.